siRNA阻断NF-κB信号通路联合5-Fu对食管鳞癌细胞周期的影响
Effect of siRNA-mediated Inhibition of NF-κB Combination with 5-Fu on Cell Cycle of ESCC Cell Lines
-
摘要: 目的利用RNAi技术特异性的抑制NF-κB亚单位p65的表达,探讨在食管鳞癌细胞中将NF-κB作为基因治疗靶点的价值。方法将荧光素标记的对照siRNA转染到食管鳞癌细胞中观察转染效率,p65siRNA转染到EC9706和Eca109细胞中,使用Western blot的方法检测p65和Cyclin D1蛋白的表达,使用EMSA法检测转染前后p65与DNA结合活性的变化;流式细胞仪检测p65siRNA与5-Fu(327μg/ml)单独或联合应用,对食管鳞癌细胞周期的影响。结果荧光素标记的siRNA转染食管鳞癌细胞的效率可达90%以上。在转染后的EC9706和Eca109细胞中,p65和Cyclin D1蛋白的表达水平下调;NF-κB与DNA的结合活性明显下降;G0/G1期的细胞开始增加,同时S期的细胞逐渐减少;当转染p65siRNA细胞联合使用5-Fu时,G0/G1期的细胞明显增加,同时S期的细胞明显减少。结论p65siRNA可以特异性的阻断NF-κB信号通路,下调NF-κB下游基因中细胞周期蛋白Cyclin D1的表达,表明活化的NF-κB信号通路可以成为食管鳞癌基因治疗中一个重要的分子靶点。Abstract: Objective RNA interference (RNAi) was employed to inhibit the expression of p65 and to evaluate the effects of NF-κB signaling pathway as a target for gene therapy in ESCC cell lines. Methods A fluorescein-labeled non-special siRNA was used to monitor efficiency in EC9706. EC9706 and Eca109 were transfected with 50 nM p65siRNA, p65 and cyclinD1 protein levels were determined using Western Blotting. After transfected with or without p65siRNA at 72h, cells were tested for nuclear activity of NF-κB using nuclear extracts by EMSA. ESCC cells were t reated with or without p65siRNA, 5-Fu or combinations thereof for 48 h. The cells were stained with PI and analyzed cell cycle by flow cytometry. Results A fluorescein-labeled non-special siRNA was used to monitor efficiency in EC9706, demonstrating nearly 90% t ransfection efficiency. The protein level of p65 and cyclinD1 decreased af ter t ransfected with p65siRNA at 72 h. And p65siRNA also suppressed the NF-κB-DNA-binding. p65siRNA-transfected cells showed an increase in the percentage of cells in the G0 / G1 phase and a decrease in the percentage of cells in the Sphase. While combination with 5-Fu, the result s were more prominence. Conclusion p65siRNA inhibit s the constitutively active NF-κB signaling pathway, and downregulat s the expression of cyclinD1. The st rong constitutive NF-κB signaling pathway in ESCC makes NF-κB a target for the development of novel therapeutic st rategies.